TR’s 7th Anniversary: Thank You

Timmerman Report is 7 years old today.

On Feb. 2, 2015, I rode my bike to the office on a wet Seattle morning and turned on the lights. I thought there was a need for clear, probing, contextual biotech journalism.

It was a leap of faith, like any entrepreneurial venture. I couldn’t have predicted 90 percent of what came next.

Thank you to all of the loyal subscribers who have made this happen.

I’m grateful to have built this platform for editorially independent biotech journalism, and to steward it as a trusted source. TR seeks to understand, to inform, to enlighten, and to challenge readers to think. It’s about exploring the frontiers of science and drug discovery, and thinking through the implications of all this work for society.

That’s not necessarily the formula for getting maximum clicks. Yet the business is thriving with record numbers of individual and group subscriptions. The Long Run podcast, similarly, has attracted an audience that has grown 40 percent year-over-year.

Looking at biotech from unusual angles.

Building Timmerman Report has opened up new avenues for me to give back, to mobilize the biotech community around good causes. My campaigns for the Climb to Fight Cancer at Fred Hutch, and Timmerman Traverse for Life Science Cares have raised more than $3.7 million combined for cancer research and anti-poverty nonprofits since 2017.

Those trips have been deeply meaningful. I’m proud that we, together, have catalyzed so much good work. This work will continue. The impact will grow.

Sometimes we all need to stop and think about what we’re doing, where we’ve come from, and where we’re going.

Thank you. For reading. For listening. For supporting quality journalism. And for doing the day-to-day, bit-by-bit work of improving human health and creating a better world.


Targeting Integrins With Small Molecules: Praveen Tipirneni on The Long Run

Today’s guest on The Long Run is Praveen Tipirneni.

Praveen is the CEO of Waltham, Mass.-based Morphic Therapeutic.

Praveen Tipirneni, CEO, Morphic Therapeutic

Morphic Therapeutic is developing oral small molecule drugs aimed at integrin targets. There’s some fascinating biology and computational technology underpinning this work, which I discussed a couple years ago on The Long Run with Morphic scientific founder Tim Springer.

Just to review the basics, Morphic knows that integrin targets ‘morph’ from one conformational state to another. The challenge is how one might use that knowledge as part of a small molecule drug development strategy.

Morphic has started off with a lead candidate against the alpha-4, beta-7 integrin target that is well validated by Takeda’s blockbuster antibody drug vedolizumab, marketed as Entyvio for inflammatory bowel disease. Morphic showed last year that its orally available small molecule could replicate the mechanism of an antibody, but in the more convenient form of an oral pill instead of an IV-infused antibody.

Praveen and his team need to show that this initial program can live up to its promise in clinical trials, and that it’s not a one-off – there are other small molecules with potential in the pipeline.

He’s a fun and engaging speaker, and I think you’ll enjoy hearing how Praveen’s career led to this point of possibility with Morphic.

Now please join me and Praveen Tipirneni on The Long Run.


Sridhar Iyengar on Figuring Out the Key Element to Success: Customer Needs

Lisa Suennen

Sridhar Iyengar (Sri) is one of those vaunted serial entrepreneurs. He had successfully sold his second company and was ready to do it all over again. 

Sri long ago learned that the trick to creating a successful startup was finding a difficult problem to solve – one that vexed companies that had money to spend.

It was 2015, and he was thinking about where to focus his entrepreneurial efforts. He reflected on challenges of his own making at previous companies.

Then he remembered. 

When Sri was leading engineering and product manufacturing at AgaMatrix more than a decade back, scale-up challenges in the commercial production process had cost the company dearly. Small shifts in the diabetes management environment led to very high device scrap rates. That meant millions of dollars down the drain, followed by many months of investigation trying to figure out how to collect data, identify the specific culprit, and act to make the problem go away.

Sridhar Iyengar, CEO, Elemental Machines

What made the problem even more painful was that it kept happening over and over. If only he had had real-time visibility into the details of the production line, this would not have been the case. 

Aha! he thought.

This is the perfect target for a solution that many companies face, especially life sciences companies, where small environmental glitches can make entire batches of product to go bad. By introducing data and analytics to the manufacturing line to enable rapid environmental and machine adjustments, Sri thought, you can create “non-linear value creation”—a small change in process which unlocks huge revenue opportunity.

“That’s the most boring problem I ever heard of,” said Sri’s constant co-founder and friend, Sonny Vu.

But to Sri, this was a personal challenge as well as a big professional opportunity. 

He himself had lost many hours of sleep over this specific problem in the past and he knew he was not alone. Sri knew more than most about sensors from his stints at AgaMatrix and Misfit Wearables. Now, instead of applying sensors to bodies, he set out to apply them to the manufacturing process. 

That insight led to the creation of Elemental Machines, a Cambridge-based company founded in 2015. The company makes connected process management sensors that enable production data analytics.

Sri and his team developed a system of simple connected sensors that can show how micro changes in environment and handling can have an outsized impact on what comes off the line. The system was fed by a symphony of potential troublemakers: humidity, visible light, ultraviolet light levels, air pressure, air quality, VOC contaminants, machine de-calibration were some of the suspects now subject to arrest. And it worked. 

But there was a problem.

Production leaders at biopharma companies would not buy. They were suspicious of putting everything into the cloud; they worried about information security; and, most of all, they worried about regulatory compliance – Elemental Machines would need to get ISO901, 27CFR Part11 and a multiplicity of other box-checking accreditations before manufacturing leaders would take a chance on the upstart company. Sri met with dozens of manufacturing leaders at biopharma companies and kept coming away without the sale. 

It wasn’t until someone suggested that biopharma research and development (R&D) labs had similar problems did Sri shift the business.

These labs dealt in materials that were the antecedents of future manufacturing lines. More importantly, biopharma products might never come to be if certain R&D failures go undetected. Best of all, the labs didn’t require the regulatory certifications that the manufacturing line did – the product could be used as is and bring a significant leap forward in simplicity, connectivity and analytic ability. 

The people running the labs quickly understood the potential value. And crucially, they didn’t see a lot of other options. Those who were gunning to build the “digital lab of the future” were unable to find simple ways of amassing the right data and bringing all their tools into one dashboard. Elemental Machines realized it could enable its own sensors to read virtually every type of environmental data point that lab instruments might throw off. Elemental could also build a system of application interfaces (APIs) that would allow R&D leaders to turn their own patchwork of hardware and sensors into a single tapestry of information read from Elemental’s small monitoring devices. 

That was the key that unlocked opportunity. Sri saw a way to turn a complicated thing for the right customers into something easy to monitor and manage. That was a way to save customers time, money and heartache.

Elemental’s first application connected cell culture incubators to look for variations in cell growth conditions (due to temperature, CO2, humidity, RPMs) to determine where points of failure may exist.  One lab tested the product and found out that fluctuating humidity was the mystery event causing their nascent medical device polymer to fail (not the human error that was previously assumed). 

Elemental even got asked to improve the age-old problem of refrigerator and freezer monitoring, a problem Sri thought to have been previously solved and commodified by others. It turned out that yes, temperature sensors were already ubiquitous, but the sensors didn’t really tell the right people about the real problem in the right way. Legacy products generally required WiFi (which can fail), wall plugs (which aren’t always nearby), and sent the alerts into the building’s alarm system, not to the lab manager. 

As a result, building security guards would routinely have to go on a treasure hunt to find the offending freezer. Elemental’s product turned out to be a better mousetrap. It relied on Bluetooth vs. WiFi, battery operation vs. wall plugs, and it provided one gateway to hundreds of devices to let lab directors know not just that someone left the fridge door open, but which one — all on one dashboard. 

One customer’s key insight was that certain refrigerators and freezers were opened and closed more than others. Now able to pinpoint the problem, the customer moved highly sensitive COVID testing reagents into rarely used freezers and refrigerators instead of storing them in the conveniently accessed ones on highly-populated routes. 

By avoiding the most-trafficked machines, the customer lost less of its precious materials. When the precious materials were lost, the lab director would know if it was because of a failed compressor, a door left ajar or a case of someone standing and staring into an open fridge for way too long, teenager-style.

The system, with its embedded artificial intelligence (AI), told the customer not just that there was a problem, but the likely root cause.

Interestingly, Elemental didn’t even need to promote the AI magic dust to drive labs’ adoption of their product. AI’s firepower wasn’t what was lacking – the void was just-in-time access to enough specific, integrated, basic information. By focusing on the small potential issues that drive big insight, a sophisticated and elegant system has led to large R&D partnerships. Big companies such as PerkinElmer and Eppendorf are using the system, along with several large pharmaceutical manufacturers, and smaller companies that include Insitro, Ginkgo Bioworks, and Quanterix. Incubators such as IndieBio and LabCentral have also adopted Elemental’s products. 

Since Elemental got itself in the door by providing something of value, the customers have gotten engaged in helping it enhance the product. The product now increasingly allows for any IOT sensor or Electronic Lab Notebook (ELN) or Laboratory Information Management System (LIMS) to connect through an open API. Some of Elemental’s clients have freestyled and thus helped the company add features for compliance monitoring, as well as location and utilization tracking of high-value assets.

Another shift, perhaps, has been moving from a sensor-focused business model to a platform one. This has been accompanied by a change in business model from charging for sensor hardware to charging a subscription for ongoing access to the platform.  

More and more data scientists are populating the halls of biopharma companies. There’s a growing focus on synthetic biology. More companies today are comfortable with the cloud. There’s a relentless appetite for more data and more analytics.

For Sri, this is affirming. But it has also reinforced what he already had learned in his prior two companies: you need to match your solution to what the market is ready to receive when it’s ready to receive it. This may mean leaping over a lower bar than what is technologically possible; but Sri has come to terms with that. He realizes that solving customer problems is what drives revenue, not seeking technical perfection.

For a PhD from Cambridge, this was a hard-won lesson, but a key shift in his own thinking that made success possible.   


A Small Step on Drug Pricing

Luke Timmerman, founder & editor, Timmerman Report

Mark Cuban, the billionaire-turned-reality TV star, made news this week with the Mark Cuban Cost Plus Drug Company.

Cuban has been saying for a while that he wants to stick it to the man. The biopharma man.

“I could make a fortune from this,” Cuban told Texas Monthly in September. “But I won’t. I’ve got enough money. I’d rather f— up the drug industry in every way possible.”

That was the warm-up act. Now we’re getting a closer look at what he has in mind.

The Cost Plus Drug company model is simple. It purchases generic drugs, marks them up by 15 percent, and sells them online to consumers. It’s a good idea. It doesn’t threaten anyone’s patents in the innovative side of the biopharma world. It threatens middlemen who make substantial profits, but create little to no value. Most people would call it fair. It’s very much unlike the byzantine, opaque and perverse system we have today that most people in the biopharma industry don’t even understand.

There’s something attractive about a simple, fair approach to drug pricing.

But we shouldn’t get carried away patting Mark Cuban on the back for his gift to America just yet. Cuban isn’t in the business of discovery and development of new drugs. That messy work – the work that advances human health – is left to others.

What the world needs is a nuanced, balanced act. The trick will be to reduce prices of generic and branded medicines, make them more easily accessible to patients, and keep the incentives for people to develop new ones.  

The Cuban model, in a way, is in keeping with the original spirit of the Hatch-Waxman Act of 1984 that created the generic small molecule pharmaceutical industry. But it’s a small bite at the apple if you think about the types of drugs we are developing in the 21st century.

Cost Plus won’t help solve the biosimilar pricing problem. It won’t get us to cheaper cell and gene therapies down the road. It doesn’t fix our broken health insurance system, in which people pay through the nose every month in premiums, and then are expected to pay a bundle more in co-pays and sky-high deductibles whenever they actually need healthcare. It doesn’t clamp down on the runaway spending and price increases at hospitals (see the latest from the Massachusetts Health Policy Commission, for what Mass General Brigham charges).

For now, in the early days, the Cuban Cost Plus Drug Company has 100 generic medicines for sale. Some of its initial batch of drugs appear to be offered at modest discounts that could probably be found at the local pharmacy. Others are available quite cheap. The breakthrough drug for chronic myeloid leukemia from two decades ago, imatinib, is now generic. It’s available at Cuban’s store for $17.10 for a month’s supply. That’s down from the usual $2,502 (can someone explain that indefensible price for a generic drug?).

The cholesterol-lowering drug atorvastatin – once marketed as Lipitor, the top-selling drug in the US — is also available dirt cheap. UCSF cardiologist Ethan Weiss was impressed.

I hope the Cost Plus Drug Company can gain access to a lot more medicines, build up a loyal customer base in the millions, and use its growing purchasing power to extract even better prices from generic manufacturers. That would be a way to help more people struggling to pay the bills.

It’s nice to look at this all play out and applaud. But that’s part of the problem. We talk, talk, talk, see something we like, click like, and move on to the next shiny thing, the next raging controversy. Too many people are watching from the bleachers, cheering and booing the heroes and villains, all while furtively hoping someone else will get in the arena to do the hard work.

Our culture craves the quick and easy solution, the shortcut, the silver bullet. Cuban will get a lot of attention in part because his message — there’s a simple solution! — appeals to this base desire for a simple one-and-done answer.

But if we think this billionaire or any other billionaire is going to ride to the rescue and solve the drug pricing problem for us, or fix the broken US healthcare system, then we’re fooling ourselves. Ask Jeff Bezos. Indulging in this fantasy is another way of letting our elected officials off the hook, letting ourselves off the hook, and kicking the can a little further down the road.

We don’t need more snide Tweets and hot takes. We need more people grinding behind the scenes to rebuild our institutions and repairing our social fabric. This means smart people from the public and private sector – people of talent and decency – working together. Even if that means working with people who we disagree with, and who sometimes hold views we find abhorrent. That’s the work required for those of us who care about democratic self-governance of the sort we’ve had for more than 200 years.

It might sound too daunting now. We’re in the middle of a bleak COVID-19 wave in the dark of winter. But if we don’t rally around solving big problems for the common good, when will we? We have been kicking the can down the road for a long time. We know we can’t count on a billionaire celebrity entertainer to come in with a catchy slogan and fix things for us.


Boston-based Akili Interactive, the digital therapeutics company that won a trailblazing FDA approval for pediatric ADHD, said it’s going public through a SPAC merger. The company is getting a $412 million in gross cash proceeds, including $100 million from Social Capital, the fund led by Chamath Palihapitiya. (TR coverage of Akili, Aug. 2020).

Amsterdam and Boston-based Leyden Labs raised $140 million in a Series B financing led by Casdin Capital and GV. The company is working on treatments to fight respiratory viruses, and it’s thinking about doing something the current vaccines aren’t good at – inducing mucosal immunity in the nose and throat membranes. The company has in-licensed PanFlu, a program developed by Janssen Pharmaceuticals against influenza A and B.

New Haven, Conn.-based Simcha Therapeutics raised $40 million in a Series B financing led by SR One. The company is taking its newly engineered form of IL-18 into the clinic for solid tumors. (TR coverage)

Emeryville, Calif.-based Kyverna Therapeutics raised $85 million in a Series B financing led by Northpond Ventures. It’s working on engineering CAR-T cells for autoimmunity. (TR coverage)

Cambridge, Mass.-based Cellino Biotech raised $80 million in a Series A financing led by Leaps by Bayer. It’s developing automation systems for cell therapy.

South San Francisco-based Fluidigm received a $250 million strategic capital infusion from Casdin Capital and Viking Global Investors. As part of the reboot, the company brought in Michael Egholm as CEO. He’s the former chief technology officer at Danaher Life Sciences. The company is also changing its name to Standard BioTools.

San Mateo, Calif.-based Sierra Oncology, after releasing positive Phase III results for its myelofibrosis drug candidate, raised $135 million in a stock offering at $27 a share.

South San Francisco-based Septerna raised $100 million in a Series A financing led by Third Rock Ventures. The company is working on small molecules against GPCR targets.

Vancouver, BC-based Zymeworks, the antibody engineering company, raised $100 million in a stock offering at $8 a share.

Cambridge, Mass.-based Epizyme raised $85 million in a stock offering at $1.50 a share.

Emeryville, Calif.-based Metagenomi raised $175 million in a Series B financing to advance its in vivo and ex vivo gene editing systems, and to expand its automation and manufacturing capabilities. PFM Health Sciences, Farallon Capital Management, and a leading global investment firm led the financing.

Massachusetts biotech firms raised a record $13.7 billion in venture capital in 2021. Wow. (Boston Globe)

Data That Mattered

San Mateo, Calif.-based Sierra Oncology, which picked up its lead asset in a Gilead garage sale, showed positive Phase III clinical trial results for momelotinib for myelofibrosis. The drug was tested in patients were who symptomatic, anemic, and had previously been treated with an approved JAK inhibitor. The Sierra drug, orally bioavailable JAK1, JAK2 and ACVR1 / ALK2 inhibitor, hit all primary and secondary endpoints. Sierra seized on the momentum from its rising stock price, and raised $135 million in a stock offering at $27 a share.

Regulatory Action

UK-based Immunocore won FDA approval for tebentafusp-tebn (Kimmtrak) for unresectable or metastatic uveal melanoma. It’s the first T cell receptor therapy approved by the FDA, and the first bispecific T cell engaging therapy for a solid tumor.

Gilead Sciences said the FDA has placed a partial clinical hold on its anti-CD47 antibody program, magrolimab, in combination with azacitadine. There appeared to be more unexpected serious adverse events in the treatment group than the control group, although Gilead didn’t specify what they were. The drug is being tested for myelodysplastic syndrome (MDS) and acute myeloid leukemia. The hold casts some doubt on the program, which Gilead paid $4.7 billion to obtain through its acquisition of Forty Seven.

New York-based TG Therapeutics said its lead program, a combo treatment for chronic lymphocytic leukemia and non-Hodgkin’s lymphoma, went on a clinical hold. The disclosure was made at an investor conference, and in writing through an 8-k filing with the SEC.

South San Francisco-based Cortexyme said the FDA placed a clinical hold on its atuzaginstat program, which is being evaluated for Alzheimer’s and Parkinson’s disease. The company said it’s doing a cost-saving plan, and will prioritize its next-generation program for Alzheimer’s.

Wilmington, Delaware-based Incyte said it is withdrawing the New Drug Application for parsaclisib, a PI3kinase delta inhibitor for lymphoma, after meetings with the FDA. The company called it a business decision based on the confirmatory study requirements from regulators.

Merck said it received a Complete Response Letter from the FDA, saying it wouldn’t approve its experimental drug for chronic cough, gefapixant. The drug was approved in Japan.

Gilead withdrew idelalisib (Zydelig) from the US market for two indications, after failing to complete the required post-marketing studies outlined when the drug received Accelerated Approval from the FDA in  2014. The drug will still be indicated for chronic lymphocytic leukemia.

  • Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy. Science Translational Medicine. Jan. 26. (Tom Uldrick et al Fred Hutchinson Cancer Research Center)
  • Stanford University scientists led by Euan Ashley set Guinness World Record with fastest DNA sequencing, completing a human genome sequence in 5 hours, 2 minutes. Stanford Medicine News. Jan. 12. (Hanae Armitage)
  • Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial. The Lancet Infectious Diseases. Jan. 24. (Deepali Kumar et al University Health Network, Toronto, Canada)
  • Clonally Expanded B Cells in Multiple Sclerosis Bind EBV EBNA1 and GlialCAM. Nature. Jan. 24. (William Robinson et al Stanford University)
Science of SARS-Cov-2
  • Omicron, the great escape artist. Nature Reviews Immunology. Jan. 11. (Alexandra Flemming)
  • Omicron’s Radical Evolution: Thirteen of Omicron’s mutations should have hurt the variant’s chances of survival. Instead, they worked together to make it thrive. NYT. Jan. 24. (Carl Zimmer)
  • Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae. Cell. Jan. 24. (Jim Heath et al Institute for Systems Biology)
  • Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses. Science Advances. Jan. 20. (Marsha Rich Rosner et al University of Chicago)
  • Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity. Science Translational Medicine. Jan. 18. (Saborni Chakraborty et al Stanford University)
  • Selection analysis identifies unusual clustered mutational changes in Omicron lineage BA.1 that likely impact Spike function. BioRxiv. Jan. 18. (Darren Martin et al University of Cape Town)
  • Structural diversity of the SARS-CoV-2 Omicron spike. BioRxiv. Jan. 26. (Sophie Gobeil et al Duke University)

Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods — United States, December 2020–January 2022. CDC Morbidity and Mortality Weekly Report.

Science Policy
  • What Japan Got Right About Covid-19. NYT. Jan. 24. (Hitoshi Oshitani)
  • The FDA said the Regeneron and Lilly neutralizing antibodies shouldn’t be used anymore to treat COVID-19 during the Omicron wave, because they aren’t effective at neutralizing the Omicron variant. WSJ. Jan. 24. (Joseph Walker)
  • COVID-19: endemic doesn’t mean harmless. Rosy assumptions endanger public health — policymakers must act now to shape the years to come. Nature. Jan. 24. (Aris Katzourakis, University of Oxford)
  • Unadjuvanted intranasal spike vaccine booster elicits robust protective mucosal immunity against sarbecoviruses. BioRxiv. Jan. 26. (Akiko Iwasaki et al Yale University).
  • A prospective cohort study of COVID-19 vaccination, SARS-CoV-2 infection, and fertility. American Journal of Epidemiology. Jan. 22. (Amelia Wesselink et al Boston University School of Public Health).
  • Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. JAMA. Jan. 25. (Matthew Oster et al Centers for Disease Control and Prevention)
  • Moderna said it began dosing in a Phase II clinical trial of its mRNA vaccine candidate for COVID-19 that’s specifically designed to elicit immunity against the Omicron variant. Pfizer and BioNTech said they have an Omicron-specific vaccine trial underway as well.
Personnel File

Belgium-based Galapagos NV hired Paul Stoffels as CEO. He’s the former chief scientific officer of Johnson & Johnson, and was closely involved in the founding of Galapagos more than 20 years ago. He replaces Otto van de Stolpe, who is retiring.

The Bill & Melinda Gates Foundation, the world’s largest philanthropy and a power player in global health and development, added a few new members to its board of trustees to shore up its rather shaky institutional governance in the wake of Bill & Melinda’s divorce. Gates Foundation CEO Mark Suzman is joining the 6-member board of trustees, along with Zimbabwean telecom billionaire Strive Masiyiwa, Minouche Shafik, director of the London School of Economics and Political Science; and Thomas Tierney, co-founder and co-chair of The Bridgespan Group, a philanthropic consulting firm. (Associated Press). For background on why the foundation needed to make this move, see this editorial from May 2021 in Project Syndicate by a couple of foundation veterans — Alex Friedman and Julie Sunderland.

Cambridge, Mass. and Switzerland-based Enzyvant hired Johanna Rossell as chief commercial officer. The company won FDA clearance in October to market a tissue-based regenerative therapy for an ultra-rare and life-threatening pediatric immunodeficiency. She most recently worked at Biogen on the ill-fated commercial launch of aducanumab (Aduhelm).

The Cystic Fibrosis Foundation, based in Bethesda, Maryland, hired Steven Rowe as its chief scientific officer.

Boston-based Expansion Therapeutics, the RNA medicines company, hired Sudhir Rao as senior vice president of business development.

Seattle-based Chinook Therapeutics, the developer of precision medicines for kidney diseases, hired Charlotte Jones-Burton as senior vice president of product development and strategy.

UK-based F2G, an antifungal developer, hired Mark Baglin as chief commercial officer and Janelle Anderson as chief business officer. Sylvie Gregoire joined as Non-Executive Director.

Philadelphia-based Adaptimmune hired Cintia Piccina as chief commercial officer.


South San Francisco-based Atara Biotherapeutics sold its operations and manufacturing facility in Thousand Oaks, Calif. to Fujifilm Diosynth Biotechnologies for $100 million upfront. The deal will lower Atara’s operating costs, keep skilled manufacturing and quality people on the job, and allow for Atara to have flexible access to facility to meet its cell therapy manufacturing needs for as long as 10 years.

Our Shared Humanity
  • What Will It Take to Vaccinate the World? Q&A With Peter Hotez. Bloomberg News. Jan. 18. (Clara Ferreira Marques)
  • Racism as a leading cause of death in the United States. BMJ. Jan. 25. (Harlan Krumholz et al Yale University)

The Genetics Society of America announced a series of awards this week, honoring Michael Lynch of Arizona State University, Margaret Fuller of Stanford University, Shirley Tilghman of Princeton University, and Harmit Malik of the Fred Hutchinson Cancer Research Center.


Antibody Engineering & Company Building: Bassil Dahiyat on The Long Run

Today’s guest on The Long Run is Bassil Dahiyat.

Bassil is the CEO of Monrovia, Calif.-based Xencor.

He’s been on a true Long Run.

Bassil Dahiyat, co-founder and CEO, Xencor

Bassil co-founded Xencor in 1997 after getting his PhD in chemistry at Caltech. He’s been through a lot of ups and downs in the biotech markets, and taken the company through a couple big strategic shifts.

The company is known for its work on engineering monoclonal antibody drugs, and engineered cytokine therapies. Few people may realize it, but the monoclonal antibody sotrovimab, developed by VIR Biotechnology and GSK as a broadly neutralizing antibody that still works against the Omicron variant of SARS-CoV-2, was made with help from the antibody engineers at Xencor.

Antibody engineering has come a long way over the past 20 years. These treatments are crucial to the present and future of medicine. Bassil has seen the evolution at close range.

Xencor is now aspiring to make a difference for its partners, but also to develop a few drugs of its own.

This is a fun, freewheeling, insightful conversation with a scientific entrepreneur.

Now, before we get started, a word from the sponsor of The Long Run.

Today’s sponsor, Answerthink, has been consistently recognized by SAP, one of the largest enterprise software companies, as a top business partner for delivering and implementing SAP solutions for small and midsized life science companies. Their SAP certified solutions designed for the Life Science Industry are preconfigured, rapidly deployable and address fundamental business and IT challenges such as:

  • Integrating your business applications
  • Delivering validated reporting
  • Increasing your speed to market
  • Support for global rollouts
  • As well as delivering a fully compliant solutions that meets FDA’s strict standards.

Explore how Answerthink can streamline your business processes to ensure growth.

Visit Answerthink.com/timmerman and get a copy of the e-book- “Top Three Barriers to Growth for Life Science Organizations.“

That’s Answerthink.com/timmerman

Now please join me and Bassil Dahiyat on The Long Run.


Brad Prosek on Getting to Know an Unconventional Acquirer

Vikas Goyal, former SVP, business development, Pandion Therapeutics (now part of Merck)

[Editor’s Note: this is the first in a monthly series with business development executives about some of the surprises, subtleties, and human aspects of biotech dealmaking.]

Cambridge, Mass.-based Constellation Pharmaceuticals lived through the ups and downs of the epigenetic drug discovery field for a decade, before it exited on a high note last year. The company was acquired by Germany-based Morphosys for $1.7 billion, or $34 a share, in June 2021.

The deal gave Morphosys access to Constellation’s two lead product candidates, pelabresib (CPI-0610), a BET inhibitor, and CPI-0209, a second-generation EZH2 inhibitor. At the time of the signing, pelabresib was in Phase III clinical development for myelofibrosis and the EZH2 inhibitor was in Phase II development for hematological and solid tumors. For some of the background on the lead program and the company journey, listen to CEO Jigar Raythatha on The Long Run podcast from December 2019.

One interesting wrinkle in this deal came in the form of a $1.4 billion upfront payment from Royalty Pharma to Morphosys.

I spoke with Brad Prosek, the chief business officer of Constellation at the time, about how this deal came to be.

Brad Prosek, former chief business officer, Constellation Pharmaceuticals

Why did the deal make sense for the two parties?

Morphosys has a long history of developing antibody and biologics products. They have close to 50 collaborations in their 30+ year history, several of which have started to pay off in terms of approved products, bringing royalties and profit shares back to Morphosys. So under the leadership of their CEO Jean-Paul Kress, they have started to turn the page from that platform basis to a product-oriented company.

I had originally reached out to them (as documented in the transaction’s 14D-9) around July 2020, though my initial outreach was not about partnering Constellation’s lead program. I had seen Morphosys print a deal with Incyte that put them on my map as a fellow traveler in the heme-onc space with money to invest in partnerships. Constellation was considering collaborations around our next generation EZH2 program. We felt our EZH2 inhibitor could be a best-in-class program and we wanted to build a data wall around the program – and we felt that with a partner we could deliver a bigger program faster than we could on our own.

As Morphosys got to know the company, I think we started to check a lot of boxes for them with respect to their growth strategy. They wanted to grow into small molecules to complement their monoclonal antibody base. They wanted to build a Boston research site. And they were looking for additional assets in the hematology and oncology spaces more broadly. So the more they looked, they liked a lot more than just what I had initially reached out to them to talk about.

How did you balance their desire to learn about Constellation more broadly vs. keeping them focused on the EZH2 program, which was your more immediate-term partnering goal?

As you’re going to do in any initial BD discussions, we did present the EZH2 program in some context – we showed our pipeline slide and maybe a strategy slide. But to focus on our objective, we did step off of that very quickly onto what I wanted to talk about. At least that was my initial approach.

Ultimately, in the subsequent discussions Morphosys asked us about pelabresib. [Pelabresib, an inhibitor of BET, was Constellation’s lead program and was in a Phase 3 clinical trial for myelofibrosis at the time of the acquisition]. They had seen some of the data we had presented publicly. We had made a few comments here and there about how excited we were in advancing the program. But I tried really hard not to get distracted by that.

I wanted to avoid the trap of getting onto the slippery slope of even discussing structures of interest. When the topic of pelabresib first came up, I had been pretty clear with them that Constellation was not interested to partner, for example, US rights for pelabresib. I tried to head that off at the pass pretty quickly.

Of course, sometimes the more you say no to someone, the more they want something. As Constellation was a public company, Morphosys had the ability to change the dialogue at any time by throwing in an unsolicited proposal. Which is what they did in October 2020. Morphosys must have done additional work on their side to get comfortable that this does check the boxes for something bigger.

How did you build your relationships within Morphosys?

In my view, you have to build multiplex conviction on the other side and use the relationships you build carefully over time to make sure things work. I got introduced to Barbara Krebs-Pohl [SVP and Head of BD&L and Alliance Management at Morphosys] through Mary Martin Roberts, a dear friend and former colleague at Biogen who had gone on to join Morphosys’ market access organization. Barbara had me talk to some of her team to begin the relationship, including Monika Bӓhner and other folks in Morphosys’ search and evaluation function.

As you know, if the technical team doesn’t have conviction, it doesn’t matter how hard you bang on the senior business leaders to make your case. Given the type of deal that I was focused on with our EZH2 program, it was OK for me to let those senior relationships recede into the background as we focused on technical discussions.

As things evolved, having had a good open relationship with Barbara from the beginning was important as we advanced through the later discussions.

How did you balance your ongoing Morphosys relationship-building with Constellation’s desire to get to the right kind of deal?

That is a constant and regular dialogue with your full management team, and sometimes on a more frequent basis with a subset of the management team.

We had what I liked to call our “Gang of Four” – our CEO Jigar Raythatha, our CFO Emma Reeve, our General Counsel Karen Valentine, and myself – that would get together sometimes a couple of times a week to share how we were thinking about things, what we were seeing, and to calibrate what made the most sense. We also regularly updated a strategy subcommittee of the Board, as well as our broader Board of Directors.

It’s good to be clear as a management team and aligned with your Board as to what your goals are for the company. Then you can use what you’re learning from the market to figure out what’s going to get you closer to your goals. Partnerships and straight financings are just two different strategic options in pursuit of your company goals.

At the end of the day, I believe in having as many options as I can on both the financing and BD fronts running in parallel as much as possible. You can’t always program that. But if you can keep things running in parallel, even if some of those options are not the right situations to pursue, it gives you the ability to really think about trade-offs. You can’t do stuff by remote control or through management consulting decks, sometimes you have to have specific opportunities with tangible trade-offs to really think about your path forward. And oftentimes it can be a bit like Goldilocks to get to the path that is just right.

What was the business situation at Constellation and why did you feel this was the right time to work with Morphosys?

It’s important to note that we had a good cash position at the time when Morphosys approached us. We had not gone out seeking an M&A. And the magic here was we had the ability in this period of time to be incredibly selective due to several other options on the table as part of our work towards 2021 goals. That allowed us to not feel like our back was against the wall to any option. So Morphosys’ proposal to us was sort of an epi-phenomenon on top of what we were already trying to execute.

Our goal was to build Constellation into a biotech company where the research engine could keep sustainably delivering even as the lead programs shifted to commercialization. We were building real conviction around pelabresib’s data and clinical opportunity. We also had a great asset in our EZH2 inhibitor and wanted to go fast with that. But wanting to move our EZH2 program fast could also create resource conflicts with the Phase 3 and additional development work on pelabresib.

As we looked at the plan to get to and through early commercialization, we had some really great options to move Constellation forward and manage our cash raises in a thoughtful way. But ultimately we were going to have to finance the company at some point. And there would be additional risk, particularly technical risk, and dilution.

So when we walked into the Board Meeting where Morphosys’ ultimate Spring 2021 M&A proposal was on the agenda, that certainty for shareholders that emerges out of an M&A process was an important consideration.

Why was Morphosys the right partner for Constellation?

Importantly, Morphosys’ proposal valued the full Constellation portfolio. We had worked to build a really exciting company with a broad drug portfolio. What Morphosys was emphatic about and has been very public about since the deal is that they came for more than just pelabresib.

Agreeing to a company sale is a multifactorial analysis, but we’re all in this business to get new therapeutic options to patients as fast as possible with as much data as possible. If that’s your lodestar and where your compass points, then the analysis of any option crystalizes around whether it helps with your goal and is it fair to shareholders. And that’s where we got comfortable with Morphosys.

Paraphrasing Jigar’s commentary, we had this vision of being a fully integrated commercial-stage company acting on a global scale with an ability to work in parallel across our portfolio. Partnering with Morphosys accelerated that vision.

Was there any dataset in particular that drove Morphosys’ interest to acquire you?

At ASH 2019, we revealed data showing proof of concept with pelabresib in front-line, JAK-naive, myelofibrosis patients. We had previously shared data in second line patients, but this first-line activity was the watershed dataset.

We knew the first-line efficacy was going to be a key dataset and we wanted the data to speak for itself. That’s part of why we did the PIPE in October 2019. The PIPE followed by the data enabled our December 2019 follow-on offering that enabled us to be choosy about where to go next.

Given you were publicly traded, how did you get comfortable that the Morphosys proposal would be attractive to your investors?

We spent a fair amount of time over the years that led up to this making sure we knew what sentiment was around all of our programs, including our lead program. So we weren’t starting from square one when Morphosys sent in their initial proposal.

There is this constant tension between looking at your company plans, the cash needs to fund that plan, the options available to raise that cash, and what taking any of those options might mean for your shareholders. Our bankers at Centerview were particularly helpful at boiling that analysis down to the potential risk versus the reward.

As a CBO, you’re not doing your job unless you have these pieces ready at hand. When the game changes as the CBO, you need to be able to confidently sit down with your CEO and your Board and say, “Here’s how we can think about this.”

How did the deal process go with Morphosys?

Every deal has lots of near-death moments. Part of what being in this CBO chair is about is thinking about and trying to anticipate what you can, having the ability to react fluidly in real-time, and always having back-ups to the back-ups to your back-up plans.

Again, you never want to end up against a wall.

One thing with respect to this deal is Morphosys had a very creative and transformational financing that they had to pull together to make this deal happen. When we started the journey with Morphosys’ first proposal in October 2020, from just looking at their financial statements, it was not clear where Morphosys would get the cash to pull off the acquisition.

This ended up becoming effectively a three-party deal with Royalty Pharma coming in with significant funding to Morphosys.

A two-handed deal is already hard to close, and a three-handed deal is very hard to pull off. This was really Morphosys’ problem and not ours, and we didn’t really see any of this come together until the very end, but a lot of this was evolving in parallel on Morphosys’ side. At the end, Jigar and Jean-Paul were communicating regularly so we did know what we needed to.

One thing I felt confident about on the BD side was that whoever Morphosys was going to talk to about their financing needs, we had probably also talked to them. Again, to keep our options open, I wanted the royalty funding groups to have a perspective on Constellation and our programs.

Deal competition also helps to signal that things are moving along, but we didn’t use that card until necessary.

When and why did you bring in Centerview?

Long before anything got hot and before anything like the deal we did with Morphosys was even apparent, I prioritized introducing Eric Tokat [a Partner at Centerview] to Jigar and the Board. An important thing to realize is that bankers like Eric and his team are not just in it for the immediate deal that you might be able to transact right now. Good bankers would far rather help you think about what your options are, would prefer you generate the best return for shareholders over the broad horizon, and ultimately may help you be acquired for more money later on instead of a deal that may be on the table today.

The Centerview team is tremendous. Eric had a long relationship with Jean-Paul Kress, which no doubt helped during the deal process. But having a good banking partner around the table will help a young company. Nobody has a monopoly on relationships, and different folks bring different perspectives and specialize in different types of deals.

You’ve done many transactions over your career – was there anything about this one that was just different?

Feedback can be a gift. I had done a lot of buy-side deals over my career, and one of my goals when joining Constellation was to do more sell-side. One of my learnings was to be incredibly diligent about asking for feedback from counter-parties, seeking clarifications, and really understanding what is happening on their side. We got a ton of free consulting from these discussions. And there is always your vision for the asset versus what is in the eye of the beholder.

And it’s important for any sell-side process to integrate the feedback you’re getting. This helped us understand what partners might have considered as warts in our programs, think of plans to maximize the value of each of our assets, and know when to come back to re-engage and update counter-parties. I really believe that this super-diligent approach to getting and integrating feedback from partners led to us having the multiple options that we did.


Beware of the Expert Fallacy, But Don’t Fall Into The Cynicism Trap

David Shaywitz

In December, a team led by two University of Pennsylvania scholars, psychologist Angela Duckworth (best known as author of Grit) and behavioral economist Katy Milkman published in Nature the results of a colossal study on behavior change.

The researchers evaluated the impact of a huge range of behavioral interventions – 54 – that were thought to potentially influence gym attendance after four weeks. 

The research – termed a “megastudy” – involved 61,293 participant subjects, and 30 scientists from 15 different U.S. universities; each of the 54 conditions were studied in groups of at least 455 participants; the average group size was over 1,000 participants.

The authors’ main area of emphasis in the paper was methodological. Successfully executing such massive a field experiment encourages other scientists to take advantage of this powerful approach, the authors contend. “By enabling direct comparisons of diverse intervention ideas,” they write, “megastudies can accelerate the generation and testing of new insights about human behavior and the relevance of these insights for public policy.”

Angela Duckworth, professor of psychology, University of Pennsylvania

What did they learn about their interventions? These data were somewhat disappointing. While nearly half the approaches worked better than the negative control, the effects, while statistically significant, were relatively small. Moreover, few approaches proved discernably better than what was essentially a standard-of-care (active) control, an approach consisting of three, evidence-based elements:

  • Planning prompts: Participants was encouraged to specifically plan the dates and times of their exercise; (this approach, called “implementation intentions” has also been used to nudge voter turnout, in work spearheaded by Todd Rodgers – see here).
  • Reminders – Participants were texted reminders at their scheduled times;
  • Microincentives – Participants received a credit, worth about 22c, for each visit.

The supplemental intervention that seems to perform the best was offering microincentives (worth 9c) to participants who had missed a workout, as an encouragement to return. This resulted in a 27% improvement over placebo (amounting to an extra 0.4 days of exercise per week), and a 16% improvement over the active control.

Unfortunately, even the relatively modest benefits of interventions dropped off rapidly after the study concluded; in other words, the interventions did not seem to impart to participants improved behavior in a particularly durable fashion.

Harvard business school professors Michael Luca and Max Bazerman summarized (prepublication) these results in their book The Power of Experiments (my WSJ review here): “behavioral interventions that led to short-term gains were less effective when looked at over a multiple-month span.”

As professor Duckworth succinctly told Luca and Bazerman: “Behavior changes are really *#$@ing hard.”

Expert Fallacy

Perhaps the most interesting aspect of the megastudy was the inclusion of predictions of intervention efficacy by a range of impartial assessors, including behavior science professors and practitioners. Not only were there “no robust correlations” between predicted and observed treatment effects, but the predictions anticipated a level of benefit that was “9.1 times too optimistic.” In other words: experts thought the interventions were going to work far, far better than was ultimately observed.

These results are consistent with the large and growing body of literature on the limitations of expert prediction (see this magnificent Louis Menand discussion of Philip Tetlock’s scholarship). The megastudy also supports expansive literature on the epidemic of overconfidence (one of Nobel laureate Daniel Kahneman’s many areas of contribution – see here). 

I’ve discussed expert fallacy and the challenge of overconfidence in a number of Wall Street Journal book reviews (including Rosenzweig’s Left Brain, Right Stuff, and The Invisible Gorilla, by Chabris and Simons). I’ve also explored these issues in the context of biopharma – see this Financial Times op-ed with Nassim Taleb, and this piece in Forbes

Between these biases, and the burgeoning literature on irreproducibility, it’s tempting to embrace the famous William Goldman observation about Hollywood, “Nobody knows anything,” and quickly find yourself in a very dark place.

But, it turns out, cynicism is probably not the right answer either.

The Cynicism Trap

You don’t have to spend much time on social media – or in late-night college bullshit sessions – to appreciate the power and appeal of cynicism, defined in an academic paper as “a negative appraisal of human nature, a belief that self-interest is the ultimate motive behind all human actions, even the seemingly good ones, and that people will go to any lengths to satisfy it.”

As Stanford psychologist Jamil Zaki reviews in a fabulous, short TED talk (“How to escape the cynicism trap” – here), while we may not enjoy the company of cynics, we tend to think they are smarter, and that their grim view of others makes them better at detecting dishonesty, for example, and hence less likely to get ripped off (not true, as Zaki reveals).

Jamil Zaki, associate professor of psychology, Stanford University

There’s also the contrasting concern that a less cynical, more hopeful and generally positive attitude, as “Freakonomics” host Steven Dubner notes, “can be seen as a sign of weakness,” and “as something that might be exploited.”

Considerable research has explored the notion of “depressive realism,” the idea that those with a negative view of the world are the ones who are seeing it most clearly, as Stephanie Bucklin nicely discusses here.

Fortunately – at least for the many optimists and aspiring optimists – the dismal view may not be right either. A fascinating 2018 study, for example, examining global data from over 200,000 people, found that while most of us “tend to believe in cynical individuals’ cognitive superiority,” the numbers don’t bear this out.

Rather, the data show that “cynical (vs. less cynical) individuals generally do worse on cognitive ability and academic competency tasks.” 

Moreover, across a range of cultures examined, “competent individuals held contingent attitudes and endorsed cynicism only if it was warranted in a given sociocultural environment. Less competent individuals embraced cynicism unconditionally.”

In other words, it’s the people who know less who tend to be reflexively cynical, while those who know more are selectively cynical. 

As the authors suggest, this could represent an adaptive posture, preventing those most vulnerable from getting taken advantage of. Causality might also work in the other direction, and those who are reflexively cynical might not open themselves up to opportunities that could expand their knowledge base.

It’s this last point – the receptivity to opportunity – that represents perhaps most compelling argument for resisting the “cynicism trap.” It’s something I’ve heard tech VCs, in particular, emphasize – the importance of being receptive to possibility, and to the outsized potential of radical new ideas. You might be wrong, they say, but you can’t lose more than the value of the investment; yet if you’re right, your upside can be almost unlimited, a return that reflexive cynics will never realize. 

As VC Balaji Srinivasan points out here, every significant advance in the technology revolution was originally dismissed by cynical industry experts. There’s a reason for the popular Silicon Valley aphorism, “pessimists sound smart; optimists make money.”

The advantages of an optimistic mindset extend far beyond the financial.

A more positive, less cynical view also enables us to derive greater joy from engagement with other people, to share in their happiness and embrace their possibility. 

Both cynical and hopeful stories, Zaki points out, can “can become self-fulfilling,” and he urges us to deliberately choose the more optimistic path. “We can be skeptical,” he says, “demanding evidence before we believe in people — but hopeful, knowing they can change for the better.”

Similarly, as Penn’s Duckworth notes in a (captivating) discussion with Steven Dubner (here), she isn’t advocating for reflexive optimism, sometimes called “toxic positivity.” 

Instead, she says, “It’s both possible to have a high center of gravity when it comes to positive emotion and to be pretty stable around that, and I think it’s possible to allow your attentional field to encompass these other things.” 

What’s critical for both optimists and pessimists to recognize, Duckworth argues, is that we have choices:

“There are virtuous and vicious cycles; being unhappy, being negative, and always being hyper-critical can really be a spiral downward. If you do pay attention to that, you could say, ‘Hey, look over here, it’s this virtuous upward spiral. I think I’m going to join that one.’”

In essence: happiness is a choice – so choose it.


The Omicron Wave: A Review of the Research on Spread and Severity

Mara Aspinall, managing director, BlueStone Venture Partners; professor of the practice, biomedical diagnostics, Arizona State University; advisor, Rockefeller Foundation

The vast majority of people in the US have at least partial immunity to many forms of SARS-CoV-2, either from prior infection, vaccination, or both.

The past few weeks have shown us that the Omicron variant transmits faster than any of its predecessors. That essentially guarantees that the unvaccinated plus early vaccinees (last dose/boost more than 6 months ago) will contract COVID-19 over the next few weeks and months. 

Early reports from hospitals are telling us that people with Omicron infections are suffering less severe symptoms. If this phenomenon — the combination of airborne transmissibility and mild lower airway symptoms holds up over time — then it is likely that COVID-19 will join the common cold, Influenza and Respiratory Syncytial Virus (RSV) among endemic infectious diseases.

We aren’t going to eradicate COVID. We’re going to have to live with it.

Let’s consider a couple key questions in some depth:

  • What evidence is there that we are entering a COVID endemic era in 2022?
  • What will a COVID endemic world look like (especially for diagnostics)?
1. What evidence is there that we are entering a COVID endemic era?

Omicron has become the dominant variant of concern in an even shorter time than Delta, the previous record holder. Because of its plethora of mutations on the Spike protein, Omicron has effective resistance to most previously developed antibody drug cocktails and substantially reduces vaccine effectiveness.

On the good news front, Omicron is causing far fewer hospitalized, ICU or ventilated patients per infection. Laboratory work suggests several compelling hypotheses of why this might be so. Our confidence is mounting that Omicron has higher transmission but lower morbidity and mortality than prior variants of concern: perhaps to the level of seasonal flu. 

However encouraging that may be, influenza fatality rates can be tragically high (e.g. 61,000 deaths in 2017-18 in the US). A world with both flu and COVID circulating at the same time will inevitably increase respiratory distress mortality and morbidity, and put tremendous pressure on hospitals.

Is there real-world evidence of lower morbidity and mortality? Early indications: Yes

The best data on Omicron comes from South Africa and the UK, where Omicron developed the earliest and where surveillance has been the most comprehensive. The UK is running about 4 weeks behind South Africa, where the drop in Omicron’s death rate was particularly striking. 

The UK pre-existing Delta death rate was already much lower than South Africa, but that too has more than halved in the Omicron era. 

The rate of asymptomatic Omicron cases is much higher than prior variants, according to a Dec. 27 study from South African researchers and colleagues at the Fred Hutchinson Cancer Research Center. Researchers found that almost one-third (31 percent) of people with HIV who enrolled in a Moderna vaccine study in South Africa in December were found to already have COVID. That’s up from about 1-2 percent of people who showed up in a comparable vaccine study months ago, when the Beta variant was circulating. These asymptomatic carriers were shown to have high levels of viral shedding based on samples from nasal swabs.

This high rate of hidden cases, and the high levels of viral shedding, means that many people will inevitably transmit their infections to others. Some of these people will end up with severe symptoms.

That’s a glimpse at the biology. Now let’s take a look at the clinical implications.

Researchers at Imperial College London looked at data from the first two weeks of December, when Omicron rose to prominence. The team reported 40-45% lower hospital admissions for Omicron versus Delta (Table 1: note UK “hospitalization” includes emergency department visits, admissions is more representative of severity). Prior infection and vaccination reduced the risk of Omicron hospital admission risk by ~70% (Table 2).

By the end of December, with more data coming in every day, the hospital admission rate in London was about 80 percent lower during this Omicron wave than the prior Delta wave.

How are the vaccines holding up?

The UK Health Security Agency has published an update on vaccine effectiveness after 198,348 UK Omicron cases (Omicron update 12/31/2021).  

Bottom-line, a two-dose mRNA vaccination series confers essentially no protection against Omicron infection after 6 months, whereas the two-dose mRNA vaccine retained ~60% effectiveness against Delta (down from 98% initially). A subsequent booster increases Omicron immunity at the 9-10 week point from a rapidly declining ~40% back up to ~50% (Pfizer boost), or ~70% (Moderna boost).

There has not yet been enough time to evaluate longer term effectiveness versus Omicron. 

Prior infection, current vaccines and boosters do reduce severity, but cannot be considered effective against infection beyond 6 months. The saving grace of the vaccines, however, can be seen in the hospitalization data referenced above. They are keeping people out of the hospitals.

There hasn’t been enough time yet to fully evaluate the US clinical experience, at least compared with the UK and South Africa. But all the signs are that it will be consistent here (for an always helpful US perspective, see Paul Sax MD’s blog of Dec. 30)

Evidence from the Laboratory to Explain Reduced Disease Severity

Over the past month, there have been many excellent studies (I have 16 on file currently and more arrive every day) examining the pathology of Omicron infection in animal models and human cell cultures. There are two arenas contributing to a consensus on why Omicron is demonstrating lower morbidity and mortality (see Eric Topol’s excellent “Ground Truths” newsletter on Substack):

Omicron infects primarily the upper respiratory tract – especially the nose and throat. That’s likely causing more coughing and viral aerosol dispersion and transmission. The virus appears to be less able to migrate further the lower respiratory tract, deep into the lungs where prior variants dramatically damage the cells – alveoli – responsible for clearing carbon dioxide and transferring essential oxygen to the bloodstream. This is an evolutionarily favorable path for viral mutation, as evidenced by Omicron’s competitive advantage over Delta, which is more efficient at getting deep into the lungs. This does not preclude a more virulent future path for Omicron, but it does reduce its likelihood.

See the following studies below for more detail:

    • Lungs have 1,000x lower viral load and no damage (12/26/21 animal model)
    • Omicron 70x higher virus in Bronchus; 10x less in lung (12/15/21 human tissue)
    • Omicron viral load and damage lower in lung (12/29/21 human tissue)
    • Cell fusion reduces white cell effectiveness, only evident in severe cases (5/12/21 Commentary/Review)
    • Damaging cell fusion (syncytia) are common in viral diseases (9/21/21 math model)
    • Omicron causes lower cell fusion closely related to pathogenicity ( animal model)
    • Lower lung absence of cleavage protein (TMPRSS) inhibits lung infection (12/22/21 cellular model)
    • Less lung infection and inflammation from Omicron (12/28/21 humanized mouse model)
    • Milder infection in all tissues, limited pathology (12/28/21 animal model)
    • Broader set of tissues infected, but less in the lungs (1/3/22 human cells)

Although neutralizing antibody counts from prior infection or vaccination do decline toward zero after 6 months, memory B cells (the cells that produce these antibodies) and memory T cells (that mobilize the immune system and attack pathogens directly) both become more broadly effective against unencountered variants after repeated prior exposures.

Generally speaking: the more exposure the better, especially with longer delays between encounters (implies minimum 12-16 week spacing of each initial and booster dose). One of the key early findings of the Omicron wave is that T-cell immunity from prior infection and vaccination appears to be longer-lasting, and this second-line of immune defense is likely a big reason why so many people are getting mild infections that don’t end up sending them to the hospital.

See a few key studies that look beyond neutralizing antibody assays below:

    • Longer infection/vaccination intervals increase resistance (1/1/22 multi-country)
    • Enhanced memory B cell effectiveness on repeated exposure (1/1/22 patient cells)
    • 70-80% of T cell effectiveness is retained across all variants (12/28/21 patient samples)
    • Omicron infection provides cross-immunity to prior variants (12/27/21 patient samples)
    • Broad immune escape but little lung damage (1/3/22 cells and epidemiology)
2. What will a COVID endemic world look like (especially for diagnostics)?

First, let’s look at this in the short term to mitigate the damage from an ongoing airborne threat.

  • In the US, we need to persist in efforts to vaccinate the remaining 40% of the population that remains unvaccinated (including children). The vaccination push should require boosters at 6 months. Efforts should continue to revise vaccines for novel-variants and conserved epitopes. If successful, these updated vaccines could be available by late 2022/early 2023
  • Continue masking in, and/or avoidance of, enclosed spaces
  • Continue and systematize surveillance through viral genomic sequencing (and PCR)
  • Empower individuals and institutions with widely available and inexpensive self-tests

There has been massive demand in the US for rapid testing. Individuals have become more familiar with self-testing. This is not about to decline. The industry needs to develop expanded availability of rapid tests to allow self-diagnosis to distinguish among the broad range of respiratory diseases – tests that can discriminate among both bacterial and viral respiratory infections – COVID-19, Influenza, RSV, tuberculosis, pneumonias etc.

Without adequate testing and surveillance, it’s hard to answer a key question — how will we know if it is “over” (at least in its current form)? 

Official counts of cases are becoming less reliable. Few of the rapid self-test results are reported to public health authorities who manage the official databases. Omicron’s increased asymptomatic cases will largely go untested — people will have COVID and walk around infecting other people without ever knowing they were positive.

In this context, reported case numbers understate the reality, even as the total number is rising exponentially. Given this reality, some have suggested we should primarily track hospital admissions since this is generally a reliable indicator of serious disease (although COVID deniers are advocating ignoring the hospitalized with COVID and only counting the hospitalized for COVID).  

Unfortunately, we now know that viral loads and hence transmission can be just as high in the asymptomatic – we cannot afford to lose track of the total number of cases.

A continuing unknown is the long-term effect of past infection. We do know that virus is found in many organs on autopsy; a trend likely exacerbated by Omicron as a result of its reduced ACE2/TMPRSS dependency. A 1/2/2022 University of Waterloo Canadian paper suggests that executive function is significantly affected during post-acute COVID-19 recovery, but we do not yet know what circumstances drive vulnerability to Long COVID-19, nor what types of infection cause it.

This is one of the big research questions that will take time to answer – to what extent does Omicron infection lead to various forms of Long COVID? What biological phenomena are driving the chronic symptoms? How many people will be affected, and for how long? What kind of symptoms will they have to endure?

It will take time to gather data to help us understand what’s going on.

It has been 100 years since the devastating 1918-1921 Influenza pandemic. That avian H1N1 virus infected one-third of the global population, with nearly 5% mortality among younger adults. We have been fortunate that COVID-19 has had a relatively low mortality rate of 1-2%, but it is clear that 21st century travel and COVID-19 show that infection can spread quickly to more than just one third of the global population – by the time this pandemic is over, 70-80% of the global population will have been exposed, infected and/or vaccinated.

We have been negligent preparing for inevitable waves of epidemic infections. We have few effective viral therapies in hand. We are rapidly exhausting the antibiotics that have protected us from bacteria scourges for the past 70 years. 

Given that it is highly unlikely that COVID-19 disappears, we are beginning the transition to an influenza-like endemic COVID: a continuing threat of more virulent mutation-fueled outbreaks driving ever-present danger to the respiratory impaired and those with compromised immunity. 

The last 50 years have taught us that animal reservoir pathogens can mutate and spread without warning — we cannot allow ourselves to fall under the spell of complacency ever again.


A Doctor’s View From the Front Line of the Omicron Wave

Alex Harding, MD. Entrepreneur in Residence, Atlas Venture; internal medicine physician, MGH

My phone buzzed with alerts about record-setting case numbers as I rushed between patients. A pile of tiny bottles with swabs floating in pink liquid accumulated while awaiting PCR testing.

Patients with coughs and sniffles lined up outside the door, waiting to be seen.

My shift as an internal medicine physician yesterday in MGH Chelsea’s urgent care facility reminded me of the early days of the pandemic.

The first wave was scary. The disease moved so fast. It was so severe. We knew so little.

We are certainly in a much better place this time around. But in terms of the raw numbers of people affected, the current wave is even worse.

On Monday, two days after Christmas, my clinic set a record for the number of patients seen. Shockingly, the rate of positive COVID tests has been 60-70% this week. That’s higher than I ever remember from the first wave. I tried to avoid eye contact with the people in the packed waiting area, as many patients waited over 3 hours to be seen.

It’s daunting as a healthcare worker to see this many people in line with COVID. But the feeling on the ground is different. Thanks to the vaccines and our familiarity with the disease, the illness severity is far less than before. We are seeing more patients with non-respiratory illnesses now than we saw in the first wave. And, after nearly two relentless years of pandemic pressure, fatigue has clearly set in among both healthcare workers and patients.

First, some numbers: I saw 19 patients during my 8-hour shift yesterday—about 3 or 4 more than I’d be able to get through in a busy shift before COVID. Of these patients, 11 had respiratory symptoms and 8 had other issues.

Remarkably, 10 of the 11 with respiratory symptoms had previously been vaccinated for COVID—6 had received 2 doses and 4 had received 3 doses. Only one of my respiratory patients, a young person who had very recently emigrated from Central America, was unvaccinated. Four of the patients I saw tested positive for COVID, below average for what my clinic has seen over the past week. These patients were mostly in their 20s to 40s, but in our clinic we are seeing patients with COVID spanning a full spectrum from infants to the elderly, with and without comorbidities.

Vaccines make all the difference

Of all the differences during this wave compared with prior COVID waves, the vaccination rate is the most important. The fact that all but one of my respiratory patients yesterday were vaccinated is both good and bad. This reflects the ability of the Omicron variant to at least partially escape immunity built up from prior rounds of vaccination or infection. That’s the bad news.

Now for the good news – these vaccinated patients with COVID had mild respiratory symptoms. They are not getting so sick that they develop Acute Respiratory Distress Syndrome (ARDS) — the kind of serious illness that requires mechanical ventilators.

Here’s what I mean by mildly ill. Almost all 11 of these patients had cold symptoms – runny nose, stuffy nose, sore throat, fatigue — but no shortness of breath. Only one patient, who was vaccinated, was slightly short of breath. None of my patients needed to be referred to the emergency department. They all went home.

The story was different in the first wave. There were days when we sent every third patient by ambulance to the emergency room—in March and April 2020, MGH had contracted with an ambulance company to keep an ambulance waiting at all times outside our front door.

Chelsea is an impoverished community of about 40,000 people, just across the Mystic River from Boston. The people who live here are  mostly immigrants from Latin America. They do a lot of low-wage jobs and have limited access to healthcare. Despite these challenges, Chelsea has a vaccination rate substantially higher than the state average—an accomplishment featured in October in the Boston Globe.

Now, during the Omicron surge, it appears Chelsea is reaping the rewards. Its residents are mostly protected from severe illness and death from COVID.

The prevalence of vaccination completely changes how I take care of each patient. The patients I am seeing are uncomfortable, with stuffy nose and sore throat. But their vital signs are usually stable. They are not struggling for air.

My risk assessment for these patients’ progression is also dramatically different. In the past, I was unable to speculate about whether a patient was likely to turn the corner soon or whether the illness would worsen. Now, I can reassure the vast majority of patients that, thanks to the vaccine, their illness is unlikely to get much worse. Usually, this means they can go home, get some rest, drink plenty of fluids, and stay away from other people until they are no longer infectious.

There are people out there disparaging the vaccines, wondering why anyone should bother if they can be vaccinated and still get sick. But the vaccines are clearly getting the job done. They are keeping people out of the ER and the ICU and the funeral home.

We know what we’re doing now

Our familiarity with COVID and how to manage its effects has progressed dramatically. In the spring of 2020, aside from a few case reports from China and Italy, we were almost flying blind. We did not know precisely how the illness was spread, who was at highest risk, and how to treat patients who were sick.

The CDC told us we did not need to wear N95 masks when seeing COVID patients (we should have). We debated whether to keep patients in negative pressure rooms (probably overkill). We worried too much about fomites—passing the virus through direct contact—and not enough about airborne aerosol spread. Protective equipment was scarce and an enormous source of anxiety for many healthcare workers.

For months, we were forced to sift through a flood of weak evidence and inference to determine how best to treat patients. For a while, ibuprofen was strictly avoided and atorvastatin and hydroxychloroquine were the mainstays of therapy (wrong on all counts).

Today, while access to outpatient treatments is still severely limited, as I’ll discuss later, we have greatly improved inpatient treatment protocols with a combination of prone positioning, tailored oxygen therapy, dexamethasone, remdesivir, and prophylactic anticoagulation. If I ever have to admit a patient to the hospital, I feel confident that they will receive care that improves their chances of recovery.

It’s not just COVID anymore

Early on, while COVID cases shot up, patients with non-COVID conditions seemed to vanish. Of course, they did not truly go away; they just stayed home, which put them at risk of deterioration without proper medical care.

That has changed. While I saw 11 respiratory patients yesterday, I also saw 8 patients without respiratory issues. I saw a patient with substance use disorder, one with a nasty nosebleed, patients with urinary infections, gastrointestinal issues, and more.

Our clinic is not just dealing with the current COVID wave. We’re dealing with our usual steady flow of sick people, plus a COVID wave on top. This makes our days busier. In the bigger picture, though, it is a relief that our patients with non-respiratory issues are getting the help they need. As long as hospitals aren’t overwhelmed with COVID patients, this will remain true.

We’re all pretty tired

It’s been almost two years of this. It feels longer. It’s natural for us all to be tired. Healthcare workers have had a particularly difficult couple of years, having seen so many sick people with so little that we could do for them. We have put our own health on the line, especially in the days before the vaccines. Some of us feel that our employers haven’t fairly recognized that sacrifice. Many healthcare organizations have experienced a higher rate of turnover than usual. That has compounded the fatigue for the people who have stayed put and had to pick up the slack.

Scared as we all were in the early days, I was exhilarated by being able to help on the front lines.

I still look forward to my clinical shifts, but my level of excitement has moderated over time.

The fatigue is not just among the healthcare workers. Our patients are also tired. Yesterday, I saw some patients who seemed nonchalant about possibly having COVID. In part, this makes sense. For low-risk, vaccinated people, COVID infection is very unlikely to be severe. But being infected with COVID still warrants more than a shrug.

There is also increasing fatalism. It’s understandable that some people would question why they should bother adhering to public health recommendations when they still have not been able to avoid getting infected. That attitude was palpable in some of my patients.

In spite of the frustrating circumstances, it is important to weigh the risks and benefits of one’s actions. For most healthy, vaccinated people, it probably doesn’t make sense to go back to a full lockdown. But it also doesn’t make sense to throw caution to the wind by abandoning masks and basic precautions. 

Some things haven’t changed

We still have very few treatments to offer outpatients with COVID.

With Omicron, we took a big step back in our therapeutic options for outpatients. The monoclonal antibodies from Regeneron and Eli Lilly were helpful against earlier variants, but don’t work against the new variant. There have been important treatments authorized by the FDA in recent weeks. But availability is limited.

Here’s the latest status for therapeutic options at my hospital:

  • Sotrovimab – This is the only broadly neutralizing monoclonal antibody available for COVID at MGH. Because of extreme scarcity, it is only being given to the highest risk patients, those who are unvaccinated and have multiple risk factors. Even among those patients, only a fraction are chosen at random to get treated.
    • (Aside: You should be uncomfortable with the concept of ‘penalizing’ people who have been vaccinated by not making this treatment available to them, but as physicians we must allocate resources to those who will most benefit and must not pass judgment against our patients based on the decisions they have made previously or the life conditions that influenced their ability to get the vaccine. Painful as it is, this is the right policy.)
  • Paxlovid – MGH is expecting to receive about 100 courses of this new oral protease inhibitor medication in the next few days. This treatment will also be restricted to the highest risk patients, similar to sotrovimab.
  • Molnupiravir – This drug, an oral polymerase inhibitor, will become available soon, and MGH is expecting to receive many more courses than it will receive of Paxlovid. However, thanks to the risk of inducing mutagenesis, it will probably be restricted to the highest risk patients who are not able to receive either sotrovimab or Paxlovid.
  • Fluvoxamine – This drug, an old selective serotonin reuptake inhibitor sometimes prescribed for depression and obsessive-compulsive disorder, is not authorized for COVID. There is some clinical data supporting its efficacy against COVID. The mechanism of action is dubious and most doctors will be reluctant to prescribe it off label. For more, see The Lancet Global Health.
  • Evusheld – This long-acting antibody cocktail was authorized early this month by the FDA for immunocompromised individuals. It can be used for prophylaxis, and it’s been shown to last 6 months. But it is not yet widely available to hospitals.

Over the next month or two, access to sotrovimab, Paxlovid, and Evusheld will hopefully improve and make a significant dent in COVID. For now, your best bet is to get a vaccine booster and wear a high-quality mask.

Public health still gets politicized

I was naïve enough to think that under Biden the CDC would regain scientific independence, but unfortunately that does not seem to have happened, at least not to the extent I had hoped.

Earlier this week, the CDC, with no data to support the decision, shortened the duration of quarantine for COVID patients from 10 days to 5 days. This news was a hot topic of conversation on the front lines. I spoke with about half a dozen patients yesterday about the CDC’s announcement. Some were uncomfortable with the change, and others were happy that they would be able to return to work sooner. In all cases, I had to discuss what the data actually show. (My advice to those patients: test before ending quarantine if possible, shorter quarantine for vaccinated than unvaccinated, and in no case less than 7 days.)

We’ll get through this

In spite of these challenges, I am confident that we are in a good position to get through this wave. Most of us are vaccinated and strongly protected against severe illness. For those who do get sick, we know how to take care of them. Hopefully, we will soon have new treatments available that will dramatically protect those who do get sick.

Vaccine misinformation has put millions of people unnecessarily at risk, but it is not too late to fix that.

Get boosted, wear a mask, and stay strong. Together, we’ll make it.


Improving Health and Wellness in 2022

David Shaywitz

As we start to think about 2022 and improving our health and wellness in the New Year, we make ambitious resolutions and urgently try to identify the optimal diet and best exercise program to achieve our health goals.

Stop Searching For The One

As intuitive as this approach sounds, it’s almost certainly the wrong mindset.

What behavior change experts, including Brad Stulberg and Steve Magness (best known for their books and for “The Growth Equation” website and podcast) as well as John Berardi (author of Changemakers, discussed here) and others all emphasize is that there generally isn’t a magic diet or exercise routine that’s intrinsically better than others. There is no fitness program that rules them all. 

While healthy eating (essentially, avoiding highly processed foods) and regular movement (get off the couch) are clearly good for you, the best routine is one you are most likely to stick with over time.

As tempting as it might be to pick some elaborate, ambitious exercise program, say, you need to ask yourself what are you truly likely to stick with; otherwise, you are just setting yourself up for the inevitable disappointment once life intervenes.

As Magness says (podcast quote edited slightly for clarity), “If you look at the research, and you look at the data on successful diets especially, there isn’t any that shows that one specific diet works better than anything else over the long haul.  When it comes to diet, what you can consistently adopt over a very long time works best.” 

Magness cautions against wasting your time seeking the “one answer” — the “magic bean” — and says if you do, “you’re just setting yourself up for failure.”

The same advice holds for exercise, Magness says. “Are there specific types of movement activity that might be slightly better or slightly worse?” he asks. “Sure. But in general, if you move sometimes long, sometimes hard, sometimes strong, you’re going to be good.”

What’s critical, Magness adds, is not to “get caught in the details, like ‘Oh, is this workout with 15 second intervals better than this one with 60 second intervals. It doesn’t freaking matter.”

Tech: Use With Caution

Can tech tools – like wearables – help us become healthier over the long term?

Well, maybe. To the extent a tracker can serve as prompt to remind you to exercise, and a community on Strava, say, can motivate your participation – great. 

But, as we’re increasingly recognizing, trackers also bring a series of challenges.  One concern is the tendency to rely on the wearable and begin to lose touch with your own body, reducing your confidence in your ability to understand the feedback your body is giving you.

Brad Stulberg, author of “The Practice of Groundedness” and “Peak Performance”

Another problem: the quality of the output of these devices depends on the quality of the input (see we discussed this summer); so if a PPG device, say, struggles to detect and measure heart rate accurate especially during physical activity, then measures derived from these measurements – independent of the intention and quality of the algorithm applied – will be suspect.

A third problem, described eloquently by Stulberg, is when “tracking becomes a religion,” an “ideology.”  He adds,

“You get all these secondary effects. Much like someone that is an evangelical devout Christian or an Orthodox Jew, you get someone that becomes an Orthodox Tracker, where their community becomes other trackers, and their whole life is dictated by eating during certain windows, breathing in certain ways, only eating certain foods, uploading everything to a computer, and pretty soon, you have no time and energy for anything else.”

He points out that while “these extreme communities” may “represent themselves publicly like the healthiest people in the world,” the reality is “unless they show me that they are living longer with higher function, they simply look like adherents to a very fervent religion to me.”

Choose (And Pursue) Goals Wisely

Other advice from experts relates to the nature of goals. While we’re tempted to focus on performance goals (an 8-minute mile, say, or 8 hours of sleep a night), experts like Stulberg, Magness, and Berardi all advise focusing instead on behavior goals, specific actions you can do, with the long-term mindset of achieving “mastery.”

Also important: pick goals and select actions that are small, realistic, and which you believe you are highly likely to consistently do; you can build on these. Also important: being kind to yourself, celebrating the progress you make and not beating yourself up when life inevitably happens.

To support yourself in pursuing the actions you plan to take, remember that your best chance of success happens when you don’t rely on will power (almost universally now believed to be inadequate to the task), but instead, modify your environment, where possible, to help you out. If you don’t want to eat candy bars, don’t keep them around the house. If you want to get to the gym in the morning, leave your stuff out and ready to go the night before.

The Value Of Community

Community can play an important role in promoting your health and well-being, at a number of levels.  For one, we’re happier when we’re part of communities and engaging with others – one of the reason the pandemic has been especially devastating. Seeking out opportunities to engage in communities, to connect in person with other people authentically, can enhance your wellbeing – and theirs.

For all the discussion of sensors and AI, I suspect the most significant contribution from digital fitness platforms – as I’ve repeated discussed in the context of Peloton – is the potential to create and nourish a sense of community. 

The huge opportunity I see here is for a wellness platform to perhaps initially attract users through sexy technology like a connected bike, rower, strength machine, or wearable, but then to view the platform as far more than a supportive environment for already fit cyclists, rowers, lifters, or gadget hounds. 

Instead, the real win (and it seems that at least Peloton may be pursuing this) is to create and nourish a far broader and more inclusive community, one that attracts and sustains individuals with a diverse range of fitness abilities, and interests, providing a range of attractive on-ramps to a range of offerings that collectively support an expansive conception of wellness.

Avoid Quick Fixes

On the other hand, there are things I’d urge you not to do in the new year, and they generally boil down to avoiding quick fixes, even (I’m tempted to say especially) if pitched as “natural.” 

I tend to be skeptical about supplementation in general, and exceptionally skeptical about the increasingly-popular idea of “precision supplementation,” which strikes me as bullshit squared. 

I’m also wary of pseudo-medical “hyperwellness” products – although a company offering a range of highly dubious offerings (including a range of “IV drip therapies”) just raised $140M from a top PE firm.  As Quizzify CEO and wellness guru Al Lewis observed, “I don’t know which of these is scariest and what went wrong with evolution that we need IV drips and intramuscular shots in order to thrive,” adding “how is half this stuff even legal?”

Recognize And Treat Obesity As A Chronic Disease

Transitioning from the overutilization of pseudo-medical treatments to underutilization of actual medical treatments, let’s spend a few minutes taking (another) hard look at the problem of severe obesity, once again benefiting from the insight of MGH physician and obesity scholar Fatima Cody Stanford.

What I’ve taken away from a long conversation with Stanford, as well as from many of her lectures, talks, and podcast appearances, is that while we’re collectively obsessed with weight loss, we really haven’t yet come to terms with obesity as a medical condition, preferring to consider it a regrettable life-style choice, rather a chronic disease such as hypertension or diabetes.

As a result, patients who suffer from severe obesity, or who are progressing in that direction, rarely receive the medical care they require, and often getting little more than vague and tepid “diet and exercise” advice, offered half-heartedly.  While doctors tend to be quick to treat the hundreds (UpToDate, as I discussed, lists over 230) of conditions associated with obesity, obesity itself tends to languish.

This is especially unfortunate, Stanford argues, because in addition to emphasizing the foundational role of diet and exercise, there are increasingly well-described roles, she says, for pharmacological treatments — which she’d like to see deployed comfortably and routinely by primary care doctors — as well as surgery (as I discussed in Forbes in 2012).

As Stanford sees it, we don’t use a teaspoon to clean up after a Boston blizzard – we use a snowplow, a tool suited to the demands of the job. Similarly, she argues patients suffering from severe obesity deserve access to appropriate tools and modalities.

Dr. Fatima Cody Stanford, obesity medicine expert, MGH

The issues around medication were captured in a very thoughtful exchange with an audience member at a talk Stanford gave in 2018 at the Radcliffe Institute (video here). 

The questioner noted that years ago, when she studied nutrition in college, “nobody gave drugs. Never.” Even more recently, she continued, “it was like a no-no. It’s like, ‘Well, why would you take amphetamines? You know, it’s really an artificial thing.’”

But Stanford’s perspective, the questioner observed, seemed strikingly different, viewing medication as a way to manage a “physical problem the person has with absorption or energy expenditure or whatever. So that’s a whole new thing.” 

Finally, she asked, when patients start medicines, “do they have to take them for life or and how much weight do you lose? And then do they plateau out? How does it really work over a long period of time?”

On the use of medicines, Stanford explained,

“I see these medications as complementary to someone that has improved already their diet quality and physical activity. These are the patients that come in and they’re doing everything right. I love what they’re doing and I’m like, ‘there’s not anything else I can do. But we do need to modify how your brain sees its weight set point.’”

In Stanford’s view, medicines for obesity, a chronic condition, need to be viewed the same way as medicines for other chronic conditions – when necessary and appropriate, they can make a difference, but typically need to be maintained for life, otherwise the condition they are treating reverts.  In a sense, it’s like you’re keeping the obesity in remission, rather than “curing” it.

I’m sorry,” Stanford explained.  “It’s the reality for patients, you know, and that’s what I tell patients before we commit to it. Because if the medicine works, then I’m going to keep you on.”

In addition to emphasizing the need for primary care doctors to become more comfortable offering medical therapies for obesity, Stanford also highlights the value of comprehensive obesity care centers like the one she’s in at MGH – and which has a waiting list of nearly 2,000 patients.

Stanford stresses the need to democratize comprehensive obesity care, and serves on the advisory board of what seems like a promising startup, Calibrate, with this medical mission; the company raised a $100M series B in late August.

Healthier Workplaces

As we find ourselves still dealing with the challenges of the pandemic, the need for a healthy workplace – as I’ve recently discussed – has only become more urgent.

Many employers have sought to address these challenges by increasing the buffet of wellness offerings; yet useful as these may be to some individuals, these offerings, although abundant, may not really address the core issue.

More promising, I suspect, is an evidence-driven approach, distilled into a toolkit, that has been developed by the Work and Well-Being Initiative, a “joint research-for-action” effort from the Harvard School of Public Health and MIT’s Sloan School of Business. 

The basic thesis goes as follows:

“Many employers, increasingly concerned about rising health care costs, have implemented corporate wellness programs that use workplaces as venues for promoting individual health behaviors (such as healthy eating and increased exercise). However, recent research demonstrates that these programs are not very effective and have only limited positive influence on employee health outcomes, medical costs, and productivity.

In contrast to wellness programs, the approach we offer in this toolkit emphasizes the importance of targeting and changing work conditions—that is, how workplace practices and relationships are designed and organized. Ample research has demonstrated that these are often the real root causes of employee ill health and stress.”

The initiative contends that “three work dynamics—job control, job demands, and social relationships at work— are root drivers of many forms of worker health,” and emphasizes that by addressing these issues organizationally, with employee/management partnership (which should be in the enlightened self-interest of both), and by also focusing on the emerging principles of promoting positive health (vs avoiding negative health; see my discussion here), healthier workplaces are possible.

What a hopeful vision for the upcoming year.

Best wishes for a healthier, happier, and more positive 2022.

Note to readers: reflecting the evolving focus of both my work and writing, the column will now be called “KindWellHealth.” It will concentrate on health, wellness, flourishing, and entrepreneurship.  The core principles and priorities are unchanged: I remain firmly grounded in science, cautiously optimistic about technology, and centered, as always, on people. Column-related inquires can now be sent to me here: Writing@KindWellHealth.com.